How to appeal an Aetna lupus & rheumatology denial

The framework that applies to your appeal

Federal law gives you the right to a full and fair internal appeal, then an external review by an independent third party.

Aetna-specific note: Owned by CVS Health since 2018. CVS Caremark is the PBM. Aetna ASA administers self-funded ERISA plans. Meritain Health is Aetna's TPA brand.

What Aetna's policy requires for lupus & rheumatology

Cited policy: Aetna Clinical Policy Bulletin: Lupkynis (Voclosporin) for Active Lupus Nephritis

Adult ≥18 yr with biopsy-proven ISN/RPS class III, IV, V, or mixed within 24 months. Active disease: UPCR ≥1.5 g/g (≥2 g/g for pure class V). eGFR >45 mL/min/1.73m² (caution 45-60). Used in combination with MMF + low-dose GC. Not concurrent with cyclosporine or tacrolimus. BP-controlled <130/80. Reauth 24 wk with UPCR reduction ≥25%; continued at 12 mo with CRR or sustained PRR.

How Aetna denies lupus & rheumatology — and how to counter it

Where Aetna pushes back: 1) Must fail full course MMF + IV cyclophosphamide first; 2) eGFR threshold not met; 3) Concurrent CNI prohibition — patient is on tacrolimus; 4) Pure class V membranous LN not covered.

Counter-arguments that hold up: AURORA-1 Lancet 2021 was specifically designed as voclosporin + MMF + low-dose GC vs MMF + low-dose GC alone — CRR 41% vs 23% at wk 52 (OR 2.65, p<0.0001). FDA Jan 22, 2021 label is ACTIVE LN, NOT post-MMF failure. KDIGO 2024 rec 1.2.1 + EULAR 2025 endorse MMF + CNI (voclosporin or tacrolimus) as INITIAL combination regimen. AURORA-2 36-mo extension confirms sustained CRR with stable eGFR. Class V was eligible in AURORA-1 (mixed III+V or IV+V). Discontinue tacrolimus to permit voclosporin transition — voclosporin has favorable PK profile (no TDM required, fixed dose).

What Aetna typically denies for lupus & rheumatology

Across Aetna's commercial and Medicare books, denials cluster around a small number of patterns. For lupus & rheumatology, expect:

• UM-2575 medical necessity denials
• Prior auth absent
• Step therapy on specialty drugs
• Out-of-network ER reduction

Treatments most often denied in this category

These are the lupus & rheumatology treatments most often flagged for prior auth, step therapy, or medical necessity review:

• Benlysta
• Saphnelo
• Lupkynis
• Hydroxychloroquine
• Mycophenolate (MMF)
• Cyclophosphamide IV

How to submit the appeal to Aetna

1. Read the denial letter — note the exact denial reason code and the appeal deadline (180 days from the date on the letter).
2. Gather supporting documentation: physician letter of medical necessity, relevant clinical notes, peer-reviewed citations supporting the treatment for your indication, and the policy or coverage document Aetna cited in the denial.
3. File the appeal through Aetna's portal (members: https://www.aetna.com ; providers: https://www.aetnaprovider.com). Standard decision returns within 30 days; expedited urgent appeals return within 72 hours.
4. If denied again, request external review by an independent reviewer within 4 months of the final internal denial. In CT, the state insurance department coordinates external review for fully-insured plans; ERISA self-funded plans use a federal external review through DOL/EBSA.

Clinician or prior-auth team handling this on the practice side? See Aetna's prior-authorization criteria by drug: Aetna PA criteria on ApprovalHelp.